BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kulke MH, Kennecke HF, Murali K, Joish VN. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study. Cancer Manag Res 2021;13:7439-46. [PMID: 34611437 DOI: 10.2147/CMAR.S330429] [Reference Citation Analysis]
2 Benson AB 3rd, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas 2020;49:408-12. [PMID: 32132510 DOI: 10.1097/MPA.0000000000001496] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Reference Citation Analysis]
4 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
5 Artale S, Barzaghi S, Grillo N, Maggi C, Lepori S, Butti C, Bovio A, Barbarini L, Colombo A, Zanlorenzi L, Castiglioni E, Trojani A. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. Nutr Cancer 2020;:1-10. [PMID: 33148022 DOI: 10.1080/01635581.2020.1838572] [Reference Citation Analysis]